MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial
Marc S. Raab, Monika Engelhardt, Antje Blank, Hartmut Goldschmidt, Hermine Agis, Igor Wolfgang Blau, Hermann Einsele, Barbara Ferstl, Natalie Schub, Christoph Röllig, Katja Weisel, Mark Winderlich, Janine Griese, Stefan Härtle, Johannes Weirather, Tiantom Jarutat, Christian Peschel, Manik Chatterjee
Topics & Concepts
MedicineMultiple myelomaOncologyMonoclonal antibodyInternal medicineRefractory (planetary science)LenalidomideClinical trialDaratumumabMonoclonalAntibodyImmunologyAstrobiologyPhysicsMultiple Myeloma Research and TreatmentsCalcium signaling and nucleotide metabolismCAR-T cell therapy research